VNRX
Volitionrx
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 2
stock price surged significantly
Significant inflow of main funds
consensus rating "Strong Buy"
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About VNRX
Volitionrx Limited
A developer of blood-based diagnostic tests used for detecting and diagnosing cancer
Healthcare Equipment and Supplies
09/24/1998
02/06/2015
American Stock Exchange
85
12-31
Common stock
1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014
--
Volitionrx Limited was incorporated under the laws of the State of Delaware on September 24, 1998. The company is a clinical-stage life sciences company dedicated to developing blood-based diagnostic tests for the detection and diagnosis of cancer and other diseases to meet the needs of accurate, fast, inexpensive, scalable diagnostic tests. To date, the company has developed 20 blood assays using its Nucleosomics biomarker-based technology platform, which can be used alone or in combination to generate cancer-specific blood test-based profiles.
Company Financials
EPS
VNRX has released its 2024 Q4 earnings. EPS was reported at -0.06, versus the expected -0.05, missing expectations. The chart below visualizes how VNRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VNRX has released its 2024 Q4 earnings report, with revenue of 191.66K, reflecting a YoY change of -21.44%, and net profit of -5.86M, showing a YoY change of 33.44%. The Sankey diagram below clearly presents VNRX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
